Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: By terms of nodal stations, zones, chains, and a composite

被引:14
作者
Zheng, Hui [1 ]
Wang, Lin-mao [1 ]
Bao, Fang [1 ]
Jiang, Ge-ning [1 ]
Xie, Hui-kang [2 ]
Ding, Jia-an [1 ]
Hu, Xue-fei [1 ]
Chen, Chang [1 ]
机构
[1] Tongji Univ, Surg Shanghai Pulm Hosp, Dept Gen Thorac, Sch Med, Shanghai 200433, Peoples R China
[2] Tongji Univ, Shanghai Pulm Hosp, Dept Pathol, Sch Med, Shanghai 200433, Peoples R China
关键词
Non-small-cell lung cancer; TNM classification; N2; stage; Lymphadenectomy; Lymphatic metastasis; Prognosis; PROGNOSTIC-FACTORS; INTERNATIONAL ASSOCIATION; NODES; METASTASIS; SURVIVAL; NUMBER; CLASSIFICATION; CHEMOTHERAPY; INVOLVEMENT;
D O I
10.1016/j.lungcan.2011.03.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: N2 non-small-cell lung cancer (NSCLC) is a heterogeneous disease with an extremely wide range of 5-year survival rates. A composite method of sub-classification for N2 is likely to provide a more accurate method to more finely differentiate prognosis of N2 disease. Methods: A total of 720 pN2 (T1-4N2M0) NSCLC cases were enrolled in our retrospective analysis of the proposed composite method. Survival rates were respectively calculated according to the N2 stratification methods: singly by "nodal stations", "nodal zones", or "nodal chains", or by combination of all three. Statistical analysis was carried out by Kaplan-Meier and Cox regression models. Results: A total of 10,199 lymph nodes (8059 mediastinal; 2140 hilar and intra-lobar) were removed. By nodal station, there were 173 cases of single-station involvement and 547 multi-stations. By nodal zone, there were 413 single-zone involvement and 307 with multiple zones. By nodal chain, there were 311 cases with single-chain and 409 multi-chain involvements. The overall 5-year survival was 20% and median survival time was 27.52 months. The 5-year survival was significantly better for cases of single-zone involvement, as compared to multi-zones (29% vs. 6%, p < 0.0001). The 5-year survival rates of single- and multi-chains involvement were 36% and 8%, respectively (p < 0.0001). When taking all of the above grouping methods into consideration, the N2 disease state could be further sub-classified into two subgroups with respective survival rates of 36% and 7% (p < 0.0001). Subgroup I was composed of individuals with single-chain involvement and having either one or two station metastasis; individuals with any other metastasis combinations formed Subgroup II. Multivariate analysis revealed that the composite sub-classification method, number of positive lymph nodes, ratio of nodal metastasis, and pT information were the most important risk factors of 5-year survival. Conclusions: By combining the three N2 stratification methods based on "stations", "zones", and "chains" into one composite method, prognosis prediction was more accurate for N2 NSCLC disease. Single nodal chain involvement, which may be either one or two nodal stations metastasis, is associated with best outcome for pN2 patients. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:497 / 503
页数:7
相关论文
共 50 条
[41]   Postoperative Radiotherapy for Patients With Completely Resected Pathologic N2 Non-Small-Cell Lung Cancer: A Retrospective Analysis [J].
Mantovani, Cristina ;
Levra, Niccolo Giaj ;
Filippi, Andrea R. ;
Novello, Silvia ;
Buffoni, Lucio ;
Ragona, Riccardo ;
Ricardi, Umberto .
CLINICAL LUNG CANCER, 2013, 14 (02) :194-199
[42]   Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial [J].
Pless, Miklos ;
Stupp, Roger ;
Ris, Hans-Beat ;
Stahel, Rolf A. ;
Weder, Walter ;
Thierstein, Sandra ;
Gerard, Marie-Aline ;
Xyrafas, Alexandros ;
Frueh, Martin ;
Cathomas, Richard ;
Zippelius, Alfred ;
Roth, Arnaud ;
Bijelovic, Milorad ;
Ochsenbein, Adrian ;
Meier, Urs R. ;
Mamot, Christoph ;
Rauch, Daniel ;
Gautschi, Oliver ;
Betticher, Daniel C. ;
Mirimanoff, Rene-Olivier ;
Peters, Solange .
LANCET, 2015, 386 (9998) :1049-1056
[43]   ACR APPROPRIATENESS CRITERIA® ON INDUCTION AND ADJUVANT THERAPY FOR STAGE N2 NON-SMALL-CELL LUNG CANCER: EXPERT PANEL ON RADIATION ONCOLOGY-LUNG [J].
Gopal, Ramesh S. ;
Dubey, Sarita ;
Rosenzweig, Kenneth E. ;
Chang, Joe Yujiao ;
Decker, Roy ;
Gewanter, Richard M. ;
Kong, Feng-Ming ;
Lally, Brian E. ;
Langer, Corey J. ;
Lee, Hoon Ku ;
Movsas, Benjamin .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (04) :969-974
[44]   Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base [J].
Robinson, Cliff G. ;
Patel, Aalok P. ;
Bradley, Jeffrey D. ;
DeWees, Todd ;
Waqar, Saiama N. ;
Morgensztern, Daniel ;
Baggstrom, Maria Q. ;
Govindan, Ramaswamy ;
Bell, Jennifer M. ;
Guthrie, Tracey J. ;
Colditz, Graham A. ;
Crabtree, Traves D. ;
Kreisel, Daniel ;
Krupnick, Alexander S. ;
Patterson, G. Alexander ;
Meyers, Bryan F. ;
Puri, Varun .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) :870-+
[45]   Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer [J].
Lei, Tao ;
Xu, Xiao-Ling ;
Chen, Wei ;
Xu, Ya-Ping ;
Mao, Wei-Min .
ONCOTARGETS AND THERAPY, 2016, 9 :921-928
[46]   Prognostic factors for post-recurrence survival in patients with completely resected Stage III (N2) non-small-cell lung cancer [J].
Cho, Sukki ;
Yum, Sungwon ;
Kim, Kwhanmien ;
Jheon, Sanghoon .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2018, 54 (03) :554-559
[47]   Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): Randomised clinical study 1988-1992 [J].
Debevec, M ;
Bitenc, M ;
Vidmar, S ;
Orel, J ;
Strojan, P ;
Kovac, V .
LUNG CANCER, 1996, 14 (01) :99-107
[48]   Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved [J].
Matsunaga, Takeshi ;
Suzuki, Kenji ;
Takamochi, Kazuya ;
Oh, Shiaki .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2014, 46 (01) :86-91
[49]   Improved Survival Associated with Neoadjuvant Chemoradiation in Patients with Clinical Stage IIIA(N2) Non-Small-Cell Lung Cancer [J].
Koshy, Matthew ;
Fedewa, Stacey A. ;
Malik, Renu ;
Ferguson, Mark K. ;
Vigneswaran, Wickii T. ;
Feldman, Lawrence ;
Howard, Andrew ;
Abdelhady, Khaled ;
Weichselbaum, Ralph R. ;
Virgo, Katherine S. .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) :915-922
[50]   Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence [J].
Le Pechoux, Cecile ;
Dunant, Ariane ;
Faivre-Finn, Corinne ;
Thomas, Pascal-Alexandre ;
Pourel, Nicolas ;
Lerouge, Delphine ;
Edwards, John ;
Van Schil, Paul ;
Rami-Porta, Ramon ;
Dansin, Eric ;
Nestle, Ursula ;
Fadel, Elie ;
Zalcman, Gerard .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (26) :2930-+